Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Mar;61(3):549-59.
doi: 10.2337/db11-1120.

Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications

Affiliations
Review

Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications

Ryoji Nagai et al. Diabetes. 2012 Mar.

Abstract

This article outlines evidence that advanced glycation end product (AGE) inhibitors and breakers act primarily as chelators, inhibiting metal-catalyzed oxidation reactions that catalyze AGE formation. We then present evidence that chelation is the most likely mechanism by which ACE inhibitors, angiotensin receptor blockers, and aldose reductase inhibitors inhibit AGE formation in diabetes. Finally, we note several recent studies demonstrating therapeutic benefits of chelators for diabetic cardiovascular and renal disease. We conclude that chronic, low-dose chelation therapy deserves serious consideration as a clinical tool for prevention and treatment of diabetes complications.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Proposed mechanisms of action of aminoguanidine as a carbonyl and dicarbonyl trap. At the top, aminoguanidine reacts with carbonyl or α-hydroxycarbonyl sugars or intermediates to form a hydrazone. At the bottom, aminoguanidine reacts with a dicarbonyl compound to form a triazine.
FIG. 2.
FIG. 2.
Structures of AGE inhibitors. A: First-generation AGE inhibitors. B: Novel LR compounds (adapted from Rahbar and Figarola [18]).
FIG. 2.
FIG. 2.
Structures of AGE inhibitors. A: First-generation AGE inhibitors. B: Novel LR compounds (adapted from Rahbar and Figarola [18]).
FIG. 3.
FIG. 3.
Structures (top panel) and proposed mechanism of action (bottom panel) of AGE breakers. According to this scheme, the dinucleophilic AGE breaker adds across a dicarbonyl AGE cross-link, followed by an internal rearrangement to cleave the dicarbonyl bond, breaking the cross-link. Following hydrolysis, the AGE breaker is regenerated, leaving a chemically inert CML on one peptide and a chemically reactive aldehyde functional group on the other peptide involved in the cross-link. (Adapted from Vasan et al. [33].)
FIG. 4.
FIG. 4.
Structures of AGE cross-links identified in tissue proteins. Lys-Arg cross-links are shown in the top panel and Lys-Lys cross-links in the lower panel. Compounds with two or three carbon cross-links, e.g., GODIC, MODIC, GOLD, MOLD, and K2P, may be derived from both carbohydrates and lipids, i.e., they are AGE/ALEs. All of these compounds are considered to be irreversible AGE cross-links in proteins. Pentosidine, the vesperlysines, crosslines, and fluorolink are fluorescent and contribute to the increase in yellow-brown color and fluorescence of collagen in diabetes and aging. GODIC, glyoxal-derived imidazolium cross-link; MODIC, methylglyoxal-derived imidazolium cross-link; GOLD, glyoxal-lysine dimer; MOLD, methylglyoxal-lysine dimer.

Similar articles

Cited by

References

    1. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008;93:1143–1152 - PubMed
    1. Tessier FJ. The Maillard reaction in the human body. The main discoveries and factors that affect glycation. Pathol Biol (Paris) 2010;58:214–219 - PubMed
    1. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405–412 - PubMed
    1. Reddy VP, Beyaz A. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov Today 2006;11:646–654 - PubMed
    1. Peyroux J, Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathol Biol (Paris) 2006;54:405–419 - PubMed

Publication types

MeSH terms

Substances